HUTCHMED (China) Limited ADR(HCM) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 4:00 PM ET (Korea 10/29 05:00)
Full metrics table
| Index | - | P/E | 130.97 | EPS (ttm) | 0.1 | Insider Own | 2.3% | Shs Outstand | 174.5M | Perf Week | -7.31% |
| Market Cap | 2.32B | Forward P/E | 28.98 | EPS next Y | 28.09% | Insider Trans | - | Shs Float | 170.5M | Perf Month | -5.87% |
| Enterprise Value | 1.06B | PEG | - | EPS next Q | 0.21 | Inst Own | 2.59% | Short Float | 0.16% | Perf Quarter | 23.68% |
| Income | 0.02B | P/S | 4.22 | EPS this Y | -86.2% | Inst Trans | 1.41% | Short Ratio | 3.96 | Perf Half Y | -0.3% |
| Sales | 0.55B | P/B | 1.84 | EPS next 5Y | - | ROA | 1.02% | Short Interest | 0.27M | Perf YTD | -0.08% |
| Book/sh | 7.23 | P/C | 1.69 | EPS past 3/5Y | - | ROE | 1.44% | 52W High | -18.43% ($16.33) | Perf Year | -9.2% |
| Cash/sh | 7.88 | P/FCF | 233.8 | Sales past 3/5Y | 8.89% 19.22% | ROIC | 1.34% | 52W Low | 36.34% ($9.77) | Perf 3Y | -27.88% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -96.21% | Gross Margin | 41.55% | Volatility(W/M) | 2.76% 2.57% | Perf 5Y | -55.7% |
| Dividend TTM | - | EV/Sales | 1.92 | Sales Y/Y TTM | -8.81% | Oper. Margin | -6.34% | ATR (14) | 0.47 | Perf 10Y | 12.12% |
| Dividend Ex-Date | - | Quick Ratio | 5.5 | EPS Q/Q | -88.2% | Profit Margin | 3.26% | RSI (14) | 42 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.64 | Sales Q/Q | 41.96% | SMA20 | -5.43% ($14.08) | Beta | 0.29 | Target Price | $20.14 |
| Payout | - | Debt/Eq | 0.07 | Earnings | 2026/7/30 | SMA50 | -2.17% ($13.62) | Rel Volume | 0.56 | Prev Close | $13.8 |
| Employees | 1796 | LT Debt/Eq | 0.06 | EPS/Sales Surpr. | -31.03% -8.51% | SMA200 | 0.59% ($13.24) | Avg Volume(3M) | 0.07M | Price | $13.32 |
| IPO | 2016/3/17 | Option/Short | Yes/Yes | Trades | 589 | Volume | 37,386 | Change | -3.48% |
🧬 A China-based biopharmaceutical company focused on developing and commercializing innovative oncology drugs. It markets in-house developed drugs, including targeted oncology therapies, in China and global markets, maintains a late-stage clinical pipeline, and expands into overseas markets through partnerships with global pharmaceutical companies. It has established itself as a China-based oncology biopharma player with proprietary cancer drug development and commercialization capabilities.
Over the past 1 year, roughly in the middle
18% below its 1-year high.
Traded less than usual. That is 56% of its average volume.
HCM has a sound balance sheet but weak earning power
Of every $100 in sales, $6.34 is lost.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -86.2% this year.
Tap to view numbers
However, it looks expensive
For a company expected to earn $100 next year, you would pay $2,898. Peers typically go for $1,511.
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -55.7%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Institutions barely hold it
Institutions hold 2.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #21 of 83 in the industry
Based on market cap of $2B.
SUPN#20 Supernus Pharmaceuticals Inc $2B PER - HCM#21 HUTCHMED (China) Limited ADR $2B PER 131.0 
PBH#22 Prestige Consumer Healthcare Inc $2B PER 13.4 
PRGO#23 Perrigo Company plc $2B PER - 
BCRX#24 Biocryst Pharmaceuticals Inc $2B PER - 
FAQ
What kind of company is HCM?
HCM belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of HCM?
The market cap of HCM is approximately $2.3B, ranking 1,944 within its sector.
What is the P/E ratio of HCM?
HCM has a P/E ratio of approximately 131.0x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for HCM?
HCM has recorded a 52-week high of $16.33 and a low of $9.77.
